Mismatch repair deficient (dMMR) mutations

Keytruda Gets Green Light from NHS for New Cancer ‘Basket’

MSD’s Keytruda (pembrolizumab) has secured a significant recommendation from the UK’s National Institute for Health and Care Excellence (NICE), signaling ...